 Platinum Compounds
"Platinum Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Inorganic compounds which contain platinum as the central atom.
| Descriptor ID |
D017671
|
| MeSH Number(s) |
D01.710
|
| Concept/Terms |
Platinum Compounds- Platinum Compounds
- Compounds, Platinum
- Platinum Compounds, Inorganic
- Compounds, Inorganic Platinum
- Inorganic Platinum Compounds
|
Below are MeSH descriptors whose meaning is more general than "Platinum Compounds".
Below are MeSH descriptors whose meaning is more specific than "Platinum Compounds".
This graph shows the total number of publications written about "Platinum Compounds" by people in UAMS Profiles by year, and whether "Platinum Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2019 | 0 | 1 | 1 | | 2018 | 1 | 0 | 1 | | 2016 | 1 | 1 | 2 | | 2012 | 1 | 1 | 2 | | 2008 | 1 | 0 | 1 | | 2006 | 0 | 2 | 2 | | 1997 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Platinum Compounds" by people in Profiles over the past ten years.
-
Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel BJ, Buss MK, Nattam SR, Hurteau J, Luo W, Curtis J, Whalen C, Kohn EC, Ivy SP, Matulonis UA. Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Ann Oncol. 2019 04 01; 30(4):551-557.
-
Ying J, Zhou D, Gu T, Huang J, Liu H. Pretreatment albumin/fibrinogen ratio as a promising predictor for the survival of advanced non small-cell lung cancer patients undergoing first-line platinum-based chemotherapy. BMC Cancer. 2019 Mar 29; 19(1):288.
-
Al Hadidi S, Aburahma A, Badami S, Upadhaya S. PARP (Poly(ADP-Ribose) Polymerase) Inhibitors in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis of Randomized Controlled Trials. Oncol Res Treat. 2018; 41(4):226-235.
-
Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Perez RP, Bauer TM, Ruiz-Soto R, Birrer MJ. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. J Clin Oncol. 2017 Apr 01; 35(10):1112-1118.
-
Lax T, Dizon DS, Birrer M, Long A, Del Carmen M, Goodman A, Krasner C, Penson RT, Growdon W, Camargo CA, Banerji A. Extended carboplatin infusion does not reduce frequency of hypersensitivity reaction at initiation of retreatment in patients with recurrent platinum-sensitive ovarian cancer. J Allergy Clin Immunol Pract. 2017 Jan - Feb; 5(1):177-178.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|